Mobile technology offers novel insights into the control and treatment of allergic rhinitis : The MASK study

Show full item record



Permalink

http://hdl.handle.net/10138/303953

Citation

MASK Study Grp , Bedard , A , Basagana , X , Anto , J M , Haahtela , T & Toppila-Salmi , S 2019 , ' Mobile technology offers novel insights into the control and treatment of allergic rhinitis : The MASK study ' , Journal of Allergy and Clinical Immunology , vol. 144 , no. 1 , pp. 135-+ . https://doi.org/10.1016/j.jaci.2019.01.053

Title: Mobile technology offers novel insights into the control and treatment of allergic rhinitis : The MASK study
Author: MASK Study Grp; Bedard, Annabelle; Basagana, Xavier; Anto, Josep M.; Haahtela, Tari; Toppila-Salmi, Sanna
Contributor: University of Helsinki, Department of Dermatology, Allergology and Venereology
University of Helsinki, HUS Inflammation Center
Date: 2019-07
Language: eng
Number of pages: 15
Belongs to series: Journal of Allergy and Clinical Immunology
ISSN: 0091-6749
URI: http://hdl.handle.net/10138/303953
Abstract: Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H-1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid-treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H-1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible.
Subject: Allergic rhinitis
antihistamines
asthma
conjunctivitis
corticosteroids
mobile health
MASK
treatment
GUIDED SELF-MANAGEMENT
VISUAL ANALOG SCALE
TRADITIONAL TREATMENT
WORK PRODUCTIVITY
ASTHMA
IMPACT
AZELASTINE
FLUTICASONE
THERAPY
QUALITY
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0091674919304269_main.pdf 1.139Mb PDF View/Open
1_s2.0_S0091674919304269_main.pdf 3.421Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record